Browsing Medicine by Author "http://dx.doi.org/10.13039/501100008530"
Now showing items 1-6 of 6
-
Artificial cornea: Past, current, and future directions
Holland, Gráinne; Pandit, Abhay; Sánchez-Abella, Laura; Haiek, Andrea; Loinaz, Iraida; Dupin, Damien; Gonzalez, Maria; Larra, Eva; Bidaguren, Aritz; Lagali, Neil; Moloney, Elizabeth B.; Ritter, Thomas (Frontiers Media, 2021-11-12)Corneal diseases are a leading cause of blindness with an estimated 10 million patients diagnosed with bilateral corneal blindness worldwide. Corneal transplantation is highly successful in low-risk patients with corneal ... -
Extracellular vesicles as modulators of wound healing
Cabral, Joana; Ryan, Aideen E.; Griffin, Matthew D.; Ritter, Thomas (Elsevier, 2018-01-31)Impaired healing of cutaneous wounds and ulcers continues to have a major impact on the quality of life of millions of people. In recent years, the capacity for stem and progenitor cells to promote wound repair has been ... -
Immunomodulatory function of licensed human bone marrow mesenchymal stromal cell-derived apoptotic bodies
Wang, Jiemin; Donohoe, Ellen; Canning, Aoife; Moosavizadeh, Seyedmohammad; Buckley, Fiona; Brennan, Meadhbh Á.; Ryan, Aideen E.; Ritter, Thomas (Elsevier, 2023-10-23)Background Mesenchymal stromal cells (MSCs) show great potential for immunomodulatory and anti-inflammatory treatments. Clinical trials have been performed for the treatment of Type 1 diabetes, graft-versus-host disease ... -
Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in mice
Treacy, Oliver; Lynch, Kevin; Murphy, Nick; Chen, Xizhe; Donohoe, Ellen; Canning, Aoife; Lohan, Paul; Shaw, Georgina; Fahy, Gerry; Ryan, Aideen E.; Ritter, Thomas (BMC, 2021-04-06)Systemic administration of mesenchymal stromal cells (MSCs) has been efficacious in many inflammatory disease settings; however, little data are available on the potential immunomodulatory effects following local MSC ... -
Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation
Lohan, Paul; Murphy, Nick; Treacy, Oliver; Lynch, Kevin; Morcos, Maurice; Bingling, Chen; Ryan, Aideen E.; Griffin, Matthew D.; Ritter, Thomas (Frontiers Media, 2018-11-20)High-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. ... -
TNF-a/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung.
Murphy, Nick; Treacy, Oliver; Lynch, Kevin; Morcos, Maurice; Lohan, Paul; Howard, Linda; Fahy, Gerry; Griffin, Matthew D.; Ryan, Aideen E.; Ritter, Thomas (Federation of American Society of Experimental Biology (FASEB), 2019-05-20)Mesenchymal stromal cells (MSCs) have shown promise as a therapy for immune-mediated disorders, including transplant rejection. Our group previously demonstrated the efficacy of pretransplant, systemic administration of ...